GlassScriptPhysician profile
Robert P Vogt
NPI 1366415788
$4,350.44
in general payments reported to CMS, 2019-2025
39 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $238 · 2021: $721 · 2022: $499 · 2023: $730 · 2024: $959 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.31 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $503.25 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $401.44 | 2019-2025 | |
| Novo Nordisk INC | $371.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $273.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.99 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $161.49 | 2022 | |
| Lilly USA, LLC | $119.40 | 2021-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $116.48 | 2024 | Voquezna |
| Allergan, INC. | $101.87 | 2019-2022 | |
| Glaxosmithkline, LLC. | $89.96 | 2019-2025 | Bexsero, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $71.51 | 2025 | Auvelity, Symbravo |
| Eisai INC. | $68.76 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $66.73 | 2023-2024 | Quviviq |
| Inspire Medical Systems, INC. | $63.58 | 2023 | Inspire |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $59.19 | 2024-2025 | Zenpep |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.61 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $52.50 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $45.87 | 2024-2025 | Krystexxa |
| Grifols USA, LLC | $42.89 | 2025 | Prolastin-C Liquid |
| Kowa Pharmaceuticals America, INC. | $41.89 | 2022-2024 | Livalo |
| Nestle Healthcare Nutrition INC. | $32.06 | 2021-2023 | |
| Boston Scientific Corporation | $31.06 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.95 | 2019-2020 | |
| Medtronic, INC. | $28.96 | 2024 | Intellis Adaptivestim |
| Antares Pharma, INC. | $28.58 | 2022 | |
| Pulmonx Corporation | $22.30 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Astellas Pharma US INC | $21.88 | 2025 | Veozah |
| Ibsa Pharma INC. | $19.79 | 2024 | Licart, Tirosint |
| Scilex Pharmaceuticals INC. | $18.70 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.60 | 2025 | Gvoke Hypopen |
| Bausch Health US, LLC | $18.27 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.94 | 2023 | |
| Cleerly, INC. | $16.82 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Vbi Vaccine (Delaware) INC. | $15.86 | 2022 | |
| Cequr Corporation | $15.03 | 2024 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $12.27 | 2019 | |
| Alfasigma USA, INC. | $11.61 | 2020 | |
| Daiichi Sankyo INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Vogt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.